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Abstract 
Purpose The glomerular filtration rate (GFR) is essential for carboplatin chemotherapy dosing, 
however, the best method to estimate GFR in patients with cancer is unknown. We identify the 
most accurate and least biased method.  
Methods Data on age, sex, height, weight, serum creatinine, and results for GFR from 
51
Cr-
EDTA excretion measurements (
51
Cr-EDTA GFR) were obtained from Caucasian patients aged 
18 years or older with histologically confirmed cancer diagnoses at the Cambridge University 
Hospital NHS Trust, UK. 
We developed a new multivariable linear model for GFR using statistical regression analysis. 
51
Cr-EDTA GFR was compared to the estimated GFR (eGFR) from seven published models and 
our new model using an internal validation data set and root-mean-squared-error (RMSE) and 
median residuals. A comparison of carboplatin dosing accuracy based on an absolute percentage 
error more than 20% (APE > 20%) was undertaken.  
Results Between August 2006 and January 2013 data from 2,471 patients were obtained. The 
new model improved the eGFR accuracy (RMSE 15.00ml/min (95% CI  14.12-16.00)) compared 
to all published models. Body surface area (BSA) adjusted CKD-EPI was the most accurate 
published models for eGFR (RMSE 16.30ml/min (95% CI 15.34-17.38)) for the internal 
validation set. Importantly, the new model reduced the fraction of patients with a carboplatin 
dose APE >20% to 14.17% in contrast to 18.62% for BSA adjusted CKD-EPI and 25.51% for 
the Cockcroft-Gault model. The results were externally validated. 
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Conclusion In a large data set, from patients with cancer, a new model improves eGFR and 
carboplatin dose calculations, when compared to BSA adjusted CKD-EPI, the model we 
identified as the best published model for determination of eGFR in patients with cancer.  
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Introduction 
The glomerular filtration rate (GFR), the fluid volume filtered from the capillaries of the renal 
glomeruli into the Bowman’s capsule per unit time, is used for calculations of carboplatin 
chemotherapy doses.
1
 A number of direct GFR measurements exist, such as the calculation based 
on clearance of chromium 51 EDTA (
51
Cr-EDTA).
2
 These methods are costly and require time 
and expertise. As a substitute, models for GFR estimation have been developed based on readily 
available data, such as serum creatinine concentrations, age, and sex of the patient.
3–11
  
 
These published models for GFR have been mainly developed for non-cancer patient populations 
that are frequently enriched for patients with chronic kidney disease. Their usefulness in patients 
with cancer has been examined using only small data sets and limitations have been 
documented.
12–16
 
 
Uncertainties regarding GFR estimation for patients with cancer represent an area of clinical 
need. Carboplatin chemotherapy doses calculated using GFR
1
 are administered to patients with 
seminoma, lung, breast, and ovarian cancer, in both adjuvant and palliative settings, where 
accurate dosing is critical to outcome and toxicity.
17–27
 In addition, GFR measurements guide 
clinicians with regard to cisplatin use, which is nephrotoxic
28, 29
 and considered with caution in 
patients with reduced renal function.
30–32
 We use the largest published oncology data set to 
identify the most accurate published model as well as to develop a new model to estimate GFR.   
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Methods 
Detailed methods and a comprehensive description of the new model development are provided 
in the supplement. 
 
Study profile and data set 
The study profile is displayed schematically in Figure 1. The full data set was compiled at the 
Cambridge University Hospital NHS Trust, UK, from Caucasian patients aged 18 years or older 
with histologically confirmed cancer diagnoses and a serum creatinine measurement within 30 
days of the 
51
Cr-EDTA GFR measurement. The data set was randomly split at a ratio of 4:1 for 
model development and internal model validation. An external validation data set of 111 male 
patients with stage 1 seminoma was obtained from the Beatson West of Scotland Cancer Centre, 
Glasgow, UK. No patient-identifiable data were used. Anonymised data included age, sex, 
height, weight, serum creatinine, and results for the accurate GFR value from 
51
Cr-EDTA 
measurements (
51
Cr-EDTA GFR). Body surface area (BSA) was calculated using the Du Bois 
equation.
33
 Height, weight and 
51
Cr-EDTA GFR were measured on the same day. 
 
Assessment of published models 
We compared the 
51
Cr-EDTA GFR with the GFR calculated using the following five published 
models, with and without BSA adjustment: Martin, Wright, Mayo, Modification of Diet in Renal 
Disease (MDRD), and chronic kidney disease epidemiology (CKD-EPI). The Cockcroft and 
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Gault and Jelliffe models which estimate creatinine clearance, an approximation of GFR, were 
also assessed.
3–10
  
 
We used the Calvert equation
1
 to compare the accuracy of a carboplatin dose with an area under 
the curve (AUC) of 5 (mg/ml/min) (AUC5) calculated from 
51
Cr-EDTA GFR with eGFR for all 
models. 
 
Model generation 
In brief, we developed a linear model for the relationship between GFR and the predicting 
variables. The Box-Cox method
34
 gave a suitable transformation to approximate normality. The 
model variables were chosen using minimisation of a five-fold cross-validation, a leave-one-out 
cross validation, and the Bayesian information criterion (BIC) in a stepwise method starting from 
a model containing only an intercept term (null model).
35–40
 To address the random component 
associated with this selection process for the five-fold cross-validation criterion, 2000 repetitions 
of the process were performed and the most frequent model was taken forward.  
 
Laboratory methods and GFR calculation 
GFR was calculated from the measurement of 
51
Cr-EDTA in three plasma samples taken over 
time after intravenous injection of 2MBq of 
51
Cr-EDTA. Serum creatinine was measured using 
the kinetic Jaffe method. 
 
7 
 
Statistics 
Median percentage error (PE), root-mean-squared error (RMSE), interquartile range (IQR) of the 
residuals, and median absolute percentage error (APE) were used to assess the accuracy of each 
GFR model for predicting measured 
51
Cr-EDTA GFR. A median APE of >20% was considered a 
clinically relevant deviation of the carboplatin dose. RMSE results are expressed with a 95% 
confidence interval (CI) calculated using the chi-squared distribution. All median statistics are 
reported with IQRs.   
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Results 
Between August 2006 and January 2013 data from 2,471 patients were obtained. The data set 
was divided randomly into data from 1,997 patients (80%) for model development and from 494 
patients (20%) for internal validation of the new model. Table 1 summarizes the patient 
characteristics that were similar between data sets. Serum creatinine and 
51
Cr-EDTA GFR were 
measured within 30 days (median 6 days, IQR 2-9 days). The median for 
51
Cr-EDTA GFR was 
81ml/min (IQR 63-103ml/min) indicating that most patients had near normal kidney function.
41
 
The external validation data set consisted of 111 patients with stage 1 seminoma, who had a 
median age of 39 years (IQR 33-46 years) and median 
51
Cr-EDTA GFR of 113ml/min, (IQR 
101-131ml/min, Table 1). 
 
We used the full data set to compare the performance of seven published candidate models and 
BSA adjusted models (Mayo, Jelliffe, MDRD, CKD-EPI). For estimating GFR, CKD-EPI is the 
most accurate model with the lowest RMSE at 21.17ml/min (95% CI  20.60-21.78). BSA 
adjustment improves accuracy for the CKD-EPI, MDRD and Jelliffe models. After BSA 
adjustment CKD-EPI has the lowest RMSE (16.63ml/min, 95% CI 16.18-17.10), is least biased 
(residual median of 0.54ml/min, IQR -10.18-9.16), and has a median PE closest to zero (-0.78%, 
IQR -14.09-11.19%), the smallest residual IQR (19.34ml/min), and the smallest median APE 
(12.33%, IQR 5.77-21.62%). 
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With regard to carboplatin doses, calculated by the Calvert equation (Dose [mg] = AUC [mg x 
min/ml] x (GFR [ml/min] + 25 [ml/min])),
1
 where dose is linearly related to GFR, the statistics 
of RMSE, residual median, and IQR of residuals, are direct reflections of the GFR results, but 
median PE and median APE are different. We determined the fraction of patients receiving doses 
with a clinically relevant APE of more than 20%, which is smallest for BSA adjusted CKD-EPI 
(17.38%). BSA adjusted CKD-EPI, therefore, is the best preforming published model for 
estimation of GFR and calculation of carboplatin dose in our data set from patients with cancer 
(Supplemental Table 2). 
 
Next, we investigated if our large data set could be used to develop a new and better model. We 
first noticed that the untransformed GFR data were not normally distributed (Supplemental 
Figure 1A and C). The Box-Cox method suggested that modelling the square root of GFR would 
satisfy the assumptions of a linear model (Supplemental Figure 1B and D).  The relationship 
between square root GFR and untransformed creatinine was not linear (Supplemental Figure 2A 
and 3E). Of several tested data transformations natural logarithmic transformation achieved the 
best linearity between GFR and the transformed creatinine (Supplemental Figure 2D and 3F). 
However, graphical analysis of the residual against transformed serum creatinine concentration 
for a simple model (a model that has the variable ln(Cre), sex and BSA) showed that further 
transformations were required (Supplemental Figure 2E). Including a quadratic and cubic term 
further improved the linearity and better modelled the complex relationship (Supplemental 
Figure 3H), and significantly improved the model (p-value <0.0001, F-test). Age, body surface 
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area, height, and weight had an approximately linear relationship with square root GFR 
(Supplemental Figure 2B-C 3A-D). 
 
For the model selection on the development dataset we used the leave-one-out, 5-fold and BIC 
criteria.  All three of our criteria selected the same model (Equation 1). The 5-fold criterion 
selected the model 854 times out of the 2000 repetitions.  
Using the internal validation data set, we compared the performance of the new model to the 
performance of the published models. Bland-Altman and residual plots indicated that the new 
model is more accurate, less biased, and less heteroscedastic, i.e. it has more constant variance in 
different sub-populations (Figure 2 and Supplemental Figure 4). These plots also demonstrate 
that the new model, CKD-EPI, and BSA adjusted CKD-EPI are least prone to overfitting. The 
new model is the most accurate and second least biased model for estimating GFR (Figure 3A 
and C, Supplemental Table 3). It has the lowest RMSE at 15.00ml/min (95% CI  14.12-16.00) 
and a median residual of 0.51ml/min (IQR -7.99-9.67). For the BSA adjusted CKD-EPI model 
the RMSE and the residual median are 16.30ml/min (95% CI 15.34-17.38) and -0.03ml/min 
(IQR -9.92-10.13), and for the Cockcroft-Gault model 23.75ml/min (95% CI 22.36-25.33) and -
0.79ml/min (-14.93-9.54), respectively (Figure 3C).  
 
We consider using the new model for calculation of carboplatin dosing for patients with cancer 
the most important area of potential clinical impact. Thus we investigated the fraction of patients 
who would have received an AUC5 carboplatin dose that deviated more than 20% from the 
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accurate dose using 
51
Cr-EDTA GFR. This fraction was smallest for the new model with an 
APE>20% of 14.17% in contrast to 18.62% for the BSA adjusted CKD-EPI and 25.51% for the 
Cockcroft-Gault model (Figure 3D and Supplemental Table 4). 
We also investigated the utility of the new model to guide prescription of cisplatin, an important 
chemotherapeutic agent that causes nephrotoxicity.
28, 29
 Of the 58 patients within the internal 
validation data set who had a measured GFR of less than 50ml/min, a value that warrants caution 
for full dose cisplatin administration,
30–32
 the new model returned an eGFR below this value for 
31 (53%) patients. This compares with 36 (62%) and 35 (60%) patients when the BSA adjusted 
CKD-EPI or the Cockcroft-Gault model were used, respectively. In turn, of the 436 patients that 
had a measured GFR of more than 50ml/min, a total of 9 (2.1%) (new model), 16 (3.7%) (BSA 
adjusted CKD-EPI), and 29 (6.7%) (Cockcroft-Gault) patients had an estimated GFR below 
50ml/min.  
 
This demonstrates limitations of point estimates. However, the new model satisfies all linear 
modelling assumption and thus predictive confidence intervals for future unobserved GFR values 
can be estimated (Figure 4). For 54 (93%) patients out of the 58 patients with a measured GFR of 
less than 50ml/min the 95% predictive confidence interval includes 50ml/min. This increased 
detection rate of “at risk” patients is offset by predictive confidence intervals that contain 
50ml/min for 158 (36%) patients with a measured GFR above 50ml/min.  
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To assess the model robustness, the variable selection process was repeated for the three criteria 
on 100 different random partitions of the full data set into development and validation data sets. 
The new model remained most frequently returned and has the form  
 
Equation 1: √GFR =  𝛽0 + 𝛽1Age + 𝛽2BSA + 𝛽3ln(Cre) + 𝛽4ln(Cre)
2 + 𝛽5ln(Cre)
3 
+(𝛽6 + 𝛽8Age){if Sex = 𝑀} + 𝛽0Age × BSA + 𝜀 
 
where the errors 𝜀 are independent, mean zero normally distributed random variables with a 
constant variance 𝜎2. The final coefficients 𝛽0, …, 𝛽8 were determined by fitting the model 
using the full data set so as to get the most accurate values (Table 2). 
 
Diagnostic plots for the new model confirmed that no single data point was influential in the full 
data set (highest Cook’s distance value: 0.094) (Supplemental Figure 5A and B). Importantly 
there was still no heteroscedasticity in the final linear model and we thus confirm that calculation 
of confidence intervals (prediction intervals) for the estimated GFR values is appropriate 
(Supplemental Figure 5C and D). 
 
Finally, we externally validated the model using a dataset from a different cancer centre. GFR 
estimation (Supplemental Table 3, Figure 3B) and dose accuracy assessment for carboplatin 
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demonstrated that the new model remained the most accurate compared to all other models. The 
RMSE for the GFR calculated with the new model was 18.94ml/min compared to 21.33ml/min 
for BSA adjusted CKD-EPI, and 32.32ml/min for Cockcroft-Gault (Figure 3B-C and 
Supplemental Table 5). The carboplatin AUC5 APE>20% was 11.71% for the new model and 
18.92% for the BSA adjusted CKD-EPI, the next best model (Figure 3D and Supplemental Table 
6). Of the 111 patients in the external validation data set 105 (94.6%) had the measured GFR 
within the 95% confidence interval (Supplemental Figure 6).   
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Discussion 
Our work is based on the analysis of data from a total of 2582 patients with cancer and reports 
two potentially practice changing results. Firstly, we find that BSA adjusted CKD-EPI is the 
most accurate and least biased published model for estimation of GFR. Secondly, we develop a 
new model that improves the estimation of GFR further and allows calculation of predictive 
confidence intervals for this estimation. Both findings will help practicing oncologists who 
prescribe platinum based chemotherapy. 
 
Determination of GFR is a cornerstone of the curative and palliative management of patients 
with carboplatin responsive cancer such as lung, ovary, triple negative and germline BRCA1/2 
mutant positive breast cancer, and seminomas.
18–27
 Carboplatin doses are most commonly 
calculated using the Calvert equation,
1
 a linear relationship between GFR and dose. GFR 
measurements or estimates therefore directly influence dose accuracy. This is important because 
Carboplatin is dose-dependently linked to tumour response and toxicities.
17
 Methods to measure 
GFR after tracer injection
2
 are laborious and expensive and not considered routine clinical 
investigations. Consequently, oncologists often rely on methods to estimate GFR from biometric 
patient data and routine blood test results, most notably serum creatinine concentration. With the 
exception of the Wright equation
8
 that investigated 100 patients with cancer, these methods have 
been developed for purposes other than chemotherapy dosing and from data of non-cancer 
populations, which are enriched for patients with impaired kidney function compared to our data 
set.  
15 
 
 
Practice changing clinical trials of carboplatin chemotherapy have employed gold standard 
51
Cr-
EDTA GFR measurements,
18–20
 creatinine clearance using the Cockcroft-Gault model,
21–23
 the 
Jelliffe model
24–27, 42
 or 24 hour urine creatinine collections.
19
 This demonstrates absence of a 
consensus. The findings of our study show that out of the published methods unadjusted CKD-
EPI predicts GFR and consequently carboplatin doses similarly well to the Jelliffe, Wright, and 
Cockcroft-Gault models in patients with cancer. We confirmed the finding of other studies that 
the inclusion of BSA in predictive models improves accuracy.
12
 BSA adjusted CKD-EPI had the 
lowest RMSE and bias, as well as the smallest carboplatin dose APE >20% and should, 
therefore, be considered the best published creatinine based GFR estimation model.  
 
Patients in the development group for the CKD-EPI model
10
 were non-cancer patients and had a 
mean GFR of 68 ml/min/1.73m
2
 and were thus different to the patient population in our study, 
the population of cancer patients who are scheduled to receive carboplatin or cisplatin 
chemotherapy. We hypothesised that we could derive a new model to predict GFR better for 
patients with cancer. We recognised that there are multiple approaches for developing a model 
for the relationship between the dependant variable, GFR, and the independent predicting 
variables. Square root transformed GFR is an approximately normally distributed variable, its 
relationship to the independent variables is approximately linear, and the resulting residuals have 
a mean of zero and constant variance. Therefore, we concluded that a linear model with this 
transformation of GFR was appropriate. Evidence from our internal and external validation work 
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suggests that our new model is the best currently available model to predict GFR in patients with 
cancer.  
From a clinical point of view, the most important advantage of our new model is a reduction in 
the fraction of patients that receive a carboplatin dose that is more than 20% different from the 
dose calculated using 
51
Cr-EDTA GFR, even when compared to the BSA adjusted CKD-EPI 
model. The absolute reduction in the external validation set is from 34.23% for the Cockcroft-
Gault and 18.92% for the BSA adjusted CKD-EPI model to 11.71% with the new model. In 
addition, we report the mean of the prediction as well as the variance and, therefore, the 
predictive confidence interval. This represents a further advantage, because it will provide 
clinicians with a gauge of the suitability to use the prediction in a given clinical context. For 
example, our analysis demonstrates that only 4 out of 58 patients from the validation data set 
with a measured GFR below 50ml/min did not contain this value in the 95% predictive 
confidence interval. We present the data for the value 50ml/min, but recognize that this value 
would be dependent on the clinical context.
30–32
 We acknowledge this fact by providing an 
estimated probability of the patient’s true GFR being below a user adjustable GFR value as part 
of an online tool to offer a clinical guide for prescription of cisplatin, a nephrotoxic 
chemotherapeutic.
28, 29
  
 
Further strengths of our study are the large data set from patients with cancer, the stringent 
methodology, and the internal and external validation of our findings. Our model is based on 
standard biometric data and can be easily used in clinical practice. The study is limited, however, 
17 
 
by the Caucasian only population, due to the single centre population demographics. Others have 
shown that adjustment factors improve GFR prediction for black patients
6, 10
 and this should be a 
priority area for future investigations. The final coefficients reported in our study may be, to a 
degree, centre-dependent as a result of centre-dependent creatinine results, a problem that has 
been addressed by international guidelines to standardise creatinine reporting
43
 which are 
implemented at our centre. Using creatinine as the main explanatory variable in predicting GFR 
has its own limitations. Other predicting variables such as Cystatin C have been used, but were 
not available to us and their usefulness in patients with cancer is uncertain, because their levels 
may fluctuate in a cancer dependent and kidney function independent manner.
44
 We also did not 
analyse measurements of albumin, muscle mass, information on dietary and fluid intake, and co-
morbidities such as diabetes mellitus. 
 
Our findings may be relevant for a broad range of clinical decision making in patients with or 
without cancer diagnoses. GFR influences clinical management in the context of drug dose 
adjustments
45
 and decision making in the context of clinical organ support.
41
 Gold standard 
51
Cr-
EDTA GFR measurement would usually not be performed in these contexts. Future research 
should also investigate if the new model can facilitate correlative and ultimately causative 
analysis of toxicity and dose accuracy relationships in clinical trials.   
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In summary, BSA adjusted CKD-EPI is the most accurate published model to predict GFR in 
patients with cancer. Our new model may present a new standard of care and should be 
investigated alongside BSA adjusted CKD-EPI in clinical practice.  
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Online tool 
The following link provides access to an online tool that is built based on the new model: 
https://sites.google.com/site/janowitzwilliamsgfr/ 
The tool provides for any given set of input data the eGFR according to the new model, an 
estimated predictive confidence interval for the true GFR (default setting at 95%), an estimated 
probability of the true GFR to be below or above an operator chosen value (default setting at 
50ml/min), along with eGFR according to BSA adjusted CKD-EPI. 
  
20 
 
Author Contributions 
Conceptualization, T.J. and E.W.; Data Accrual and Review, T.J., E.W., A.M., N.A., P.B.T, 
S.J.S, S.S., J.W., P.B.M., and H.E.; Methodology, T.J., E.W., A.L., and S.T.; Formal Analysis, 
T.J. and E.W.; Statistical Review, T.J., E.W., A.M., P.B.T., S.J.S., A.L., and S.T.; Resources, 
T.J., D.I.J., S.T. and H.E.; Writing – Original Draft, T.J. and E.W.; Writing – Review & Editing, 
All Authors; Visualization, T.J. and E.W.; Funding Acquisition, T.J., D.I.J., and S.T.; 
 
Acknowledgement 
We thank all patients. We also thank the University of Cambridge, Cancer Research UK, and 
Hutchison Whampoa Limited. T.J. was supported by the Wellcome Trust Translational Medicine 
and Therapeutics Programme and the University of Cambridge Department of Oncology ( 
RJAG/076 ). HME was supported by the NIHR Cambridge Biomedical Research Centre and the 
University of Cambridge.  
21 
 
References 
1. Calvert BAH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: prospective evaluation of 
a simple formula based on renal function. J Clin Oncol 7:1748–1756, 1989 
2. Chantler C, Garnett ES, Parsons V, et al: Glomerular filtration rate measurement in man by the 
single injection methods using 51Cr-EDTA. Clin Sci 37:169–80, 1969 
3. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 
16:31–41, 1976 
4. Jelliffe RW: Letter: Creatinine clearance: bedside estimate. Ann Intern Med 79:604–605, 1973 
5. Martin L, Chatelut E, Boneu A, et al: Improvement of the Cockcroft-Gault equation for 
predicting glomerular filtration in cancer patients. Bull Cancer 85:631–636, 1998 
6. Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular 
filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461–470, 
1999 
7. Levey A, Coresh J, Greene T, et al: Using Standardized Serum Creatinine Values in the 
Modification of Diet in Renal Disease Study Equation for Estimating Glomerular. Ann Intern 
Med 145:247–254, 2006 
8. Wright JG, Boddy  a V, Highley M, et al: Estimation of glomerular filtration rate in cancer 
patients. Br J Cancer 84:452–459, 2001 
9. Rule AD, Larson TS, Bergstralh EJ, et al: Using serum creatinine to estimate glomerular 
filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 141:929–
937, 2004 
22 
 
10. Levey AS, Stevens LA, Frcp C, et al: A new equation to estimate glomerular filtration rate. 
Ann Intern Med 150:604–612, 2009 
11. Stevens LA, Coresh J, Greene T, et al: Assessing kidney function—measured and estimated 
glomerular filtration rate. N Engl J Med 354:2473–2483, 2006 
12. Ainsworth NL, Marshall A, Hatcher H, et al: Evaluation of glomerular filtration rate 
estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease 
(MDRD) formulae in oncology patients. Ann Oncol 23:1845–1853, 2012 
13. Cathomas R, Klingbiel D, Geldart TR, et al: Relevant risk of carboplatin underdosing in 
cancer patients with normal renal function using estimated GFR: lessons from a stage I 
seminoma cohort. Ann Oncol 25:1591–1597, 2014 
14. Quinton A, Lewis P, Ali P, et al: A comparison of measured and estimated glomerular 
filtration rate for carboplatin dose calculation in stage I testicular seminoma. Med Oncol 30:1–5, 
2013 
15. Kaag D: Carboplatin dose calculation in lung cancer patients with low serum creatinine 
concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors. Lung 
Cancer 79:54–58, 2013 
16. Trobec K, Knez L, Meško Brguljan P, et al: Estimation of renal function in lung cancer 
patients. Lung Cancer 76:397–402, 2012 
17. Jodrell DI, Egorin MJ, Canetta RM, et al: Relationships between carboplatin exposure and 
tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520–528, 1992 
18. Hughes A, Calvert P, Azzabi A, et al: Phase I clinical and pharmacokinetic study of 
23 
 
pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 
20:3533–3544, 2002 
19. Oliver RTD, Mason MD, Mead GM, et al: Radiotherapy versus single-dose carboplatin in 
adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366:293–300, 2005 
20. Zweifel M, Jayson GC, Reed NS, et al: Phase II trial of combretastatin A4 phosphate, 
carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 
22:2036–2041, 2011 
21. De Santis M, Bellmunt J, Mead G, et al: Randomized phase II/III trial assessing 
gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced 
urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin 
Oncol 30:191–199, 2011 
22. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing 
bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously 
untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184–2191, 
2004 
23. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al: Pegylated liposomal doxorubicin 
and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive 
ovarian cancer in late relapse. J Clin Oncol 28:3323–3329, 2010 
24. du Bois A, Herrstedt J, Hardy-Bessard A-C, et al: Phase III trial of carboplatin plus paclitaxel 
with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 
28:4162–4169, 2010 
24 
 
25. Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in 
combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, 
randomised controlled trial. Lancet 374:1331–1338, 2009 
26. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared 
with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A 
Gynecologic Oncology Group study. J Clin Oncol 21:3194–3200, 2003 
27. Pfisterer J, Plante M, Vergote I, et al: Gemcitabine plus carboplatin compared with 
carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of 
the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699–4707, 2006 
28. DeConti RC, Toftness BR, Lange RC, et al: Clinical and pharmacological studies with cis-
diamminedichloroplatinum (II). Cancer Res 33:1310–5, 1973 
29. Miller RP, Tadagavadi RK, Ramesh G, et al: Mechanisms of Cisplatin Nephrotoxicity. 
Toxins (Basel) 2:2490–2518, 2010 
30. Hanna N, Neubauer M, Yiannoutsos C, et al: Phase III study of cisplatin, etoposide, and 
concurrent chest radiation with or without consolidation docetaxel in patients with inoperable 
stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin 
Oncol 26:5755–5760, 2008 
31. Galsky MD, Hahn NM, Rosenberg J, et al: Treatment of Patients With Metastatic Urothelial 
Cancer “Unfit” for Cisplatin-Based Chemotherapy. J Clin Oncol 29:2432–2438, 2011 
32. Kintzel PE, Dorr RT: Anticancer drug renal toxicity and elimination: dosing guidelines for 
altered renal function. Cancer Treat Rev 21:33–64, 1995 
25 
 
33. Du Bois D, Du Bois EF: A formula to estimate the approximate surface area if height and 
weight be known. Nutrition 5:303–313, 1916 
34. Box GEP, Cox DR: An analysis of transformations. J R Stat Soc Ser B 211–252, 1964 
35. Zhang P: Model selection via multifold cross validation. Ann Stat 21:299–313, 1993 
36. Burman P: A comparative study of ordinary cross-validation, v-fold cross-validation and the 
repeated learning-testing methods. Biometrika 76:503–514, 1989 
37. Shao J: Linear model selection by cross-validation. J Am Stat Assoc 88:486–494, 1993 
38. Schwarz G: Estimating the dimension of a model. Ann Stat 6:461–464, 1978 
39. Van der Borght K, Van Craenenbroeck E, Lecocq P, et al: Cross-validated stepwise 
regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance 
associated mutations. BMC Bioinformatics 12:386, 2011 
40. Hastie T, Tibshirani R, Friedman J: The Elements of Statistical Learning Second Edi. 
Springer Series in Statistics, 2009 
41. Levey A, Coresh J, Balk E, et al: National Kidney Foundation practice guidelines for chronic 
kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137–147, 2003 
42. Powell MA, Filiaci VL, Rose PG, et al: Phase II evaluation of paclitaxel and carboplatin in 
the treatment of carcinosarcoma of the uterus: A gynecologic oncology group study. J Clin 
Oncol 28:2727–2731, 2010 
43. Myers GL, Miller WG, Coresh J, et al: Recommendations for improving serum creatinine 
measurement: a report from the Laboratory Working Group of the National Kidney Disease 
Education Program. Clin Chem 52:5–18, 2006 
26 
 
44. Kos J, Stabuc B, Cimerman N, et al: Serum cystatin C, a new marker of glomerular filtration 
rate, is increased during malignant progression. Clin Chem 44:2556–7, 1998 
45. Matzke GR, Aronoff GR, Atkinson AJ, et al: Drug dosing consideration in patients with 
acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global 
Outcomes (KDIGO). Kidney Int 80:1122–1137, 2011 
  
27 
 
Figure titles and legends 
 
Figure 1: Schematic representation of study workflow 
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Figure 2: Bland-Altman plots of estimated GFR and measured GFR for the new model and 
each of the published models. The average of measured GFR (mGFR) and estimated GFR 
(eGFR) was plotted against the difference of the two for the internal validation data set. Positive 
differences indicate underestimation and negative difference indicate overestimation. The plots 
are ordered in ascending order of RMSE of eGFR from top left to bottom right.  
The solid line on each plot represents the mean of the difference and the dashed line are drawn at 
the mean plus or minus 1.96 times the standard deviation of the difference. Points are coloured 
by sex, red = female, turquoise = male. 
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Figure 3: Graphical illustrations of statistics used to compare the new model and published 
models. (A-B) Boxplots of the residuals (measured GFR minus estimated GFR) for all published 
models and the new model using the internal validation data set (A) and the external validation 
data set (B) are shown. Notches delineate an approximate 95% confidence interval for the 
median residual, calculated as ±1.58*IQR/n
0.5
. A positive or negative value for the residual 
median indicates underestimation or overestimation bias respectively. (C) Graphical illustration 
of GFR RMSE in the internal and external validation data sets. Error bars describe the 95% 
confidence interval based on the Chi-squared distribution for the calculated RMSE. (D) 
30 
 
Graphical illustration of percentage of patients with a carboplatin dosing APE >20% in the 
internal and external validation datasets. For all plots: black = internal validation set; grey = 
external validation data set 
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Figure 4: Predictive confidence intervals for GFR of each patient in the internal validation 
data set.  To obtain this figure the new model fitted on the development data set was applied to 
all patients in the internal validation data set. The measured GFR (red points) and the estimated 
GFR (black points) for each patient are illustrated. Each horizontal line represents a 95% 
predictive confidence interval for the patient, with patients ordered in accession by their 
estimated GFR. The vertical dashed line highlights the boundary at a GFR of 50ml/min below 
which cisplatin administration would be considered with caution by most clinicians. Out of the 
494 patients in the internal validation data set, 24 (4.9%) have measured values outside their 
prediction interval. 
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Table titles and legends 
 Full data set (n=2471) Development (n=1977) Internal validation (n=494) External validation (n=111) 
  Median (IQR) Range   Median (IQR) Range   Median (IQR)  Range   Median (IQR)  Range   
Age [Years] 61 (50-69) 18-92 61 (50-69) 18-92 63 (51-70) 18-89 39 (33-46) 21-69 
Weight [kg] 73 (62-85) 37-163 74 (63-86) 37-149 73 (62-84) 42-163 86 (76-98) 51-161 
Height [cm] 168 (161-176) 125-200 168 (161-176) 125-200 168 (160-175) 146-196 178 (174-182) 131-192 
BSA [m
2
] 
1.84 (1.67-
2.00) 1.24-2.79 
1.84 (1.67-
2.00) 
1.24-2.67 
1.83 (1.67-
1.99) 
1.31-2.79 2.04 (1.92-2.15) 1.48-2.73 
Serum creatinine [mg/dL] 
0.91 (0.77-
1.07)  0.29-5.62 
0.91 (0.77-
1.07) 
0.38-4.05 
0.91 (0.77-
1.08) 
0.29-5.62 0.92 (0.81-1.01) 0.62-1.45 
51
Cr-EDTA GFR [ml/min] 81 (63-103) 11-211 82 (64-103) 13-211 80 (62-103) 11-187 113 (101-131) 45-202 
  
51
Cr-EDTA GFR 
subgroup n (%) 
n (%) n (%) n (%) 
    <40 ml/min 117 (5) 86 (4) 31 (6) 0 (0) 
    40-60 ml/min 422 (17) 336 (17) 86 (17) 2 (2) 
    >60 ml/min 1932 (78) 1555 (79) 377 (76) 109 (98) 
 
Sex n (%) n (%) n (%) n (%) 
    Female 1398 (57) 1114 (56) 284 (57) 0 (0) 
    Male 1073 (43) 863 (44) 210 (43) 111 (100) 
 
Table 1. Patient characteristics 
GFR = glomerular filtration rate 
IQR = interquartile range 
BSA = body surface are 
2 
 
 
Variable Coefficient Estimate Std. error t-value p-value* 
Intercept 𝜷𝟎 1.813953 0.626 2.9 0.0038 
Age 𝜷𝟏 0.01914 0.010 1.83 0.0688 
BSA 𝜷𝟐 4.732776 0.355 13.34 <0.0001 
ln(Cre) 𝜷𝟑 -3.71619 0.086 -43.33 <0.0001 
ln(Cre)
2
 𝜷𝟒 -0.9142 0.117 -7.83 <0.0001 
ln(Cre)
3
 𝜷𝟓 1.062836 0.132 8.03 <0.0001 
SexM 𝜷𝟔 0.020197 0.174 0.12 0.907 
Age:BSA 𝜷𝟕 -0.0297 0.006 -4.92 <0.0001 
Age:SexM 𝜷𝟖 0.012465 0.003 4.31 <0.0001 
 
Table 2. Final coefficients for new model 
The table describes the coefficients (𝛽𝑖, 𝑖 = 0, … , 8) of the final model (Equation 1) with the estimate value and standard deviation for 
each coefficient. The estimate for standard deviation of the residuals (𝜎) was 0.8417 to 4 significant figures.  
* From t-test comparing coefficient value to 0  
BSA = body surface area  
Cre = blood serum creatinine 
SexM = variable equals 1 if Sex is male, 0 otherwise 
x1:x2 indicates interaction variable between variables x1 and x2  
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